Residency · Residency · Cardiothoracic Surgery
Type B Aortic Dissection: Medical, Endovascular, and Surgical Management
Overview
Type B aortic dissection involves the descending aorta distal to the left subclavian artery without ascending aortic involvement. Unlike Type A dissection, uncomplicated Type B dissection is initially managed medically, with intervention reserved for complications or, increasingly, for preemptive aortic remodeling. This chapter covers classification, medical management, TEVAR indications, and the evidence base from landmark trials.
Classification
Complicated vs. Uncomplicated
Complicated Type B dissection requires urgent or emergent intervention and includes rupture or impending rupture (hemothorax, periaortic hematoma), malperfusion syndrome (visceral, renal, or limb ischemia), refractory pain despite adequate analgesia, refractory hypertension despite maximal medical therapy, and rapid aortic expansion exceeding 10 mm in the acute phase. Uncomplicated Type B dissection has no immediate life-threatening complications and is managed with medical therapy initially, though debate exists about whether preemptive TEVAR improves long-term outcomes.
High-Risk Features for Uncomplicated Type B
Several anatomic features predict aneurysmal degeneration and may support early TEVAR. These include a false lumen diameter greater than 22 mm, total aortic diameter exceeding 40 mm at presentation, an entry tear on the greater curvature, partial false lumen thrombosis (which carries a worse prognosis than complete thrombosis or complete patency), and bloody pleural effusion.
Medical Management
Acute Phase (First 14 Days)
Patients require ICU monitoring with continuous arterial blood pressure and heart rate measurement. Anti-impulse therapy is the cornerstone: IV esmolol or labetalol is first-line, targeting a heart rate below 60 bpm and systolic blood pressure of 100-120 mmHg. If blood pressure is not controlled with beta-blocker alone, IV nicardipine or nitroprusside is added. The beta-blocker must always be given first, followed by the vasodilator, to reduce dP/dt — the shear force on the aortic wall. Pain is controlled with IV opioids, with the understanding that pain may be a marker of ongoing dissection. Serial imaging with CTA at 48-72 hours assesses stability, repeated at discharge. Patients are transitioned to oral antihypertensives before discharge.
Chronic Phase
Lifelong antihypertensive therapy (beta-blocker based, with a systolic blood pressure target below 130 mmHg) is mandatory. Serial imaging with CTA or MRA is obtained at 1, 3, 6, and 12 months, then annually, monitoring for false lumen expansion, aortic diameter growth exceeding 4 mm per year, and aneurysm formation. Indications for late intervention include diameter exceeding 55-60 mm, growth exceeding 10 mm per year, or symptoms.
Endovascular Management (TEVAR)
Indications for TEVAR
TEVAR is a Class I indication for complicated acute Type B dissection with rupture, malperfusion, or refractory pain and hypertension. For subacute or early chronic Type B dissection with high-risk features, preemptive TEVAR to promote aortic remodeling is a Class IIa indication with growing evidence. TEVAR is also indicated for chronic aneurysmal degeneration when the aortic diameter exceeds 55-60 mm.
Technical Considerations
The primary entry tear is covered with a stent graft. The proximal landing zone follows the Ishimaru classification, with Zone 2 (distal to the left common carotid) potentially requiring left subclavian artery coverage with or without revascularization. Left subclavian revascularization (carotid-subclavian bypass or transposition) is recommended when covering Zone 2, especially in patients with a dominant left vertebral artery, LIMA-LAD graft, left arm dialysis access, or incomplete circle of Willis. Graft oversizing is limited to 5-10% relative to the true lumen (not the total aortic diameter) in the acute setting to avoid retrograde Type A dissection. The distal extent covers as much of the entry tear as needed while avoiding the celiac axis. Access is typically transfemoral, with an iliac conduit used when needed.
Goals of TEVAR
The goals are to seal the entry tear and direct flow into the true lumen, depressurize the false lumen to promote thrombosis and remodeling, prevent rupture and aneurysm formation, and restore true lumen perfusion to malperfused branches.
Complications of TEVAR
Retrograde Type A dissection occurs in 2-4% of cases and is the most feared complication, potentially requiring emergent open surgery. Endoleak — persistent perfusion of the false lumen — may result from proximal seal failure (Type Ia) or intercostal branch backflow (Type II). Stroke can result from coverage of arch branches or embolization. Spinal cord ischemia is a concern particularly with extensive coverage of the descending aorta and intercostal arteries. Access complications include iliac dissection and rupture.
<image>Illustration of TEVAR for acute complicated Type B aortic dissection. Panel A shows a pre-intervention CTA sagittal reconstruction with the dissection flap beginning distal to the left subclavian artery, extending to the abdominal aorta, with the entry tear on the greater curvature and a compressed true lumen. Panel B shows the deployment of a thoracic stent graft covering the entry tear with the proximal landing zone just distal to the left subclavian artery origin. Panel C shows the post-TEVAR result with the entry tear sealed, the true lumen expanded, and the false lumen beginning to thrombose. Branch vessel perfusion (celiac, SMA, renals) is restored through the expanded true lumen. Zones of the aortic arch (Ishimaru classification 0-4) are labeled for reference.</image>
Landmark Trials
INSTEAD Trial (2009)
This randomized controlled trial enrolled 140 patients with uncomplicated subacute or chronic Type B dissection, randomized to TEVAR plus medical therapy versus medical therapy alone. At 2 years, there was no difference in all-cause mortality, though TEVAR did promote aortic remodeling with false lumen thrombosis. The INSTEAD-XL 5-year follow-up (2013) demonstrated that TEVAR plus medical therapy improved aorta-specific survival (6.9% versus 19.3%, p=0.04), reduced disease progression, and decreased the need for late reintervention. Overall mortality showed a trend toward benefit with TEVAR (11.1% versus 19.3%). This landmark extension supports preemptive TEVAR in uncomplicated Type B dissection to promote aortic remodeling and reduce late aortic events.
ADSORB Trial (2014)
This RCT of 61 patients with acute uncomplicated Type B dissection demonstrated that TEVAR improved aortic remodeling (false lumen thrombosis, true lumen expansion) at 1 year. However, the trial was limited by its small sample size, short follow-up, and lack of power for clinical endpoints. It supports the concept of early intervention for aortic remodeling.
Landmark Trials in Type B Dissection
| Trial | Design | Population | Key Finding |
|---|---|---|---|
| INSTEAD (2009) | RCT, n=140 | Uncomplicated subacute/chronic Type B | No difference in 2-yr all-cause mortality; TEVAR promoted remodeling |
| INSTEAD-XL (2013) | 5-yr follow-up of INSTEAD | Same | TEVAR improved aorta-specific survival (6.9% vs. 19.3%, p=0.04); reduced disease progression |
| ADSORB (2014) | RCT, n=61 | Acute uncomplicated Type B | TEVAR improved aortic remodeling at 1 yr; underpowered for clinical endpoints |
Ongoing/Recent Trials
The ROADMAP Study is an observational study refining high-risk criteria for early TEVAR in uncomplicated Type B dissection. The ATTENTION Trial is a larger RCT evaluating early TEVAR in acute uncomplicated Type B dissection, with results maturing.
Open Surgical Management
Current Role
Open surgery for Type B dissection has largely been replaced by TEVAR. Remaining indications include situations where TEVAR is not feasible due to anatomy or access limitations, connective tissue disorders (Marfan, Loeys-Dietz) where TEVAR outcomes may be worse due to fragile tissue, chronic aneurysmal degeneration requiring extent II-IV thoracoabdominal repair, and failed TEVAR requiring conversion to open repair.
Technique
The operation is performed through a left thoracotomy or thoracoabdominal incision depending on extent. Circulatory support includes left heart bypass (left atrium to femoral artery) or full CPB. The involved aortic segment is replaced with a graft. Intercostal arteries from T8 to L1 are reimplanted for spinal cord protection, and visceral branches (celiac, SMA, renal arteries) are reimplanted for thoracoabdominal repairs. The morbidity profile is significant, with paraplegia rates of 5-10%, renal failure, and respiratory complications.
<image>Decision algorithm for management of acute Type B aortic dissection. The flowchart begins with classification into complicated versus uncomplicated. Complicated Type B (rupture, malperfusion, refractory pain/hypertension) is directed to urgent TEVAR. Uncomplicated Type B branches into two pathways: patients with high-risk features (false lumen > 22 mm, total diameter > 40 mm, partial thrombosis, greater curvature tear) are considered for preemptive TEVAR in the subacute phase (2-6 weeks), while those without high-risk features receive medical management alone with serial imaging surveillance. Long-term surveillance endpoints are shown: aneurysmal degeneration (> 55 mm or rapid growth) triggers late TEVAR or open repair. Evidence citations (INSTEAD-XL, ADSORB) are noted at each decision point.</image>
Clinical Pearls
Uncomplicated Type B dissection has a 30-day mortality of approximately 10% with medical therapy alone — this is a medical emergency requiring ICU monitoring, not a benign condition. The distinction between complicated and uncomplicated Type B dissection determines initial management: complicated equals urgent TEVAR, while uncomplicated equals medical therapy with selective intervention. INSTEAD-XL showed that preemptive TEVAR improves aorta-specific survival at 5 years, and early intervention for aortic remodeling is gaining acceptance, especially in patients with high-risk anatomic features. Partial false lumen thrombosis is a worse prognostic sign than complete thrombosis or complete patency because it creates a pressurized cul-de-sac prone to aneurysmal degeneration. Retrograde Type A dissection is the most feared complication of TEVAR (2-4%), and risk is minimized by avoiding excessive oversizing in the acute setting (limited to 5-10% of true lumen). Left subclavian artery coverage during TEVAR should be accompanied by revascularization when possible, particularly with a dominant left vertebral artery, LIMA graft, or left-sided dialysis access. Connective tissue disorders (Marfan, Loeys-Dietz) are relative contraindications to TEVAR due to fragile aortic tissue and higher rates of stent graft-related complications — open surgery may be preferred.
References
- Nienaber CA, Kische S, Rousseau H, et al. INSTEAD-XL: Aortic dissection Type B: aorta remodeling after thoracic endovascular aortic repair. Circulation. 2013;128(19):2130-2138.
- Brunkwall J, Kasprzak P, Verhoeven E, et al. ADSORB Trial: Endovascular repair of acute uncomplicated aortic Type B dissection. Eur Heart J. 2014;35(28):1835-1842.
- Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873-2926.
- Czerny M, Schmidli J, Adler S, et al. 2024 EACTS/STS Guidelines for the management of acute and chronic aortic diseases. Eur J Cardiothorac Surg. 2024;65(1):ezad426.
- VIRTUE Registry Investigators. The VIRTUE Registry of type B thoracic dissections. J Thorac Cardiovasc Surg. 2014;148(6):2726-2732.
